Multicenter, Open-label, Randomized, Controlled Parallel-group Study to Assess Discontinuation Rates, Bleeding Patterns, User Satisfaction and Adverse Event Profile of LCS12 in Comparison to Etonorgestrel Subdermal Implant Over 12 Months of Use in Women 18 to 35 Years of Age.

Trial Profile

Multicenter, Open-label, Randomized, Controlled Parallel-group Study to Assess Discontinuation Rates, Bleeding Patterns, User Satisfaction and Adverse Event Profile of LCS12 in Comparison to Etonorgestrel Subdermal Implant Over 12 Months of Use in Women 18 to 35 Years of Age.

Completed
Phase of Trial: Phase III

Latest Information Update: 23 Mar 2016

At a glance

  • Drugs Levonorgestrel (Primary) ; Etonogestrel
  • Indications Pregnancy
  • Focus Adverse reactions; Registrational
  • Sponsors Bayer; Bayer HealthCare
  • Most Recent Events

    • 23 Mar 2016 Results published in the Fertility and Sterility.
    • 09 Mar 2015 Planned End Date changed from 1 Jun 2015 to 1 May 2015 as reported by ClinicalTrials.gov.
    • 06 May 2014 The trial status is completed in Sweden, as reported by EudraCT.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top